Critical Comparison: Ayala Pharmaceuticals (NASDAQ:ADXS) versus Synaptogenix (NASDAQ:TAOX)

Synaptogenix (NASDAQ:TAOX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Valuation and Earnings

This table compares Synaptogenix and Ayala Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$772,499.00	37.39	-$28.74 million	($3.85)	-1.00
Ayala Pharmaceuticals	$3.24 million	11.05	-$48.07 million	($5.02)	-0.12

Synaptogenix has higher earnings, but lower revenue than Ayala Pharmaceuticals. Synaptogenix is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Synaptogenix and Ayala Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Ayala Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Synaptogenix and Ayala Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Ayala Pharmaceuticals	0	0	0	0	0.00

Risk & Volatility

Synaptogenix has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.